



US 20020045271A1

(19) **United States**

(12) **Patent Application Publication** (10) **Pub. No.: US 2002/0045271 A1**  
**HUSSAIN et al.** (43) **Pub. Date: Apr. 18, 2002**

(54) **COMPOUNDS AND METHODS FOR IDENTIFYING COMPOUNDS THAT INTERACT WITH MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN BINDING SITES ON APOLIPOPROTEIN B AND MODULATE LIPID BIOSYNTHESIS**

(75) **Inventors: M. MAHMOOD HUSSAIN, ARDMORE, PA (US); AHMED BAKILLAH, PHILADELPHIA, PA (US)**

**Correspondence Address:  
JANE MASSEY LICATA  
66 E MAIN STREET  
MARLTON, NJ 08053**

(73) **Assignee: LICATA AND TYRRELL P.C.**

(\*) **Notice:** This is a publication of a continued prosecution application (CPA) filed under 37 CFR 1.53(d).

(21) **Appl. No.: 09/309,668**

(22) **Filed: May 11, 1999**

**Related U.S. Application Data**

(63) **Non-provisional of provisional application No. 60/088,767, filed on Jun. 10, 1998.**

**Publication Classification**

(51) **Int. Cl.<sup>7</sup> ..... G01N 33/543**

(52) **U.S. Cl. .... 436/518**

(57) **ABSTRACT**

Methods of identifying compositions which inhibit lipid and lipoprotein secretion are provided using in vitro assays measuring inhibition of the binding of microsomal triglyceride transfer protein to a specific microsomal triglyceride binding site on apolipoprotein B and lipid complexes.

**COMPOUNDS AND METHODS FOR IDENTIFYING  
COMPOUNDS THAT INTERACT WITH  
MICROSOMAL TRIGLYCERIDE TRANSFER  
PROTEIN BINDING SITES ON APOLIPOPROTEIN  
B AND MODULATE LIPID BIOSYNTHESIS**

[0001] This application claims benefit under 35 U.S.C. Section 119(e) from the United States provisional application, Serial No. 60/088,767, filed Jun. 10, 1998.

[0002] This invention was made in the course of research sponsored by the National Institutes of Health. The U.S. Government may have certain rights in this invention.

**BACKGROUND OF THE INVENTION**

[0003] Apolipoprotein B (apoB), a translational product of the apoB gene, is an essential structural protein required for the assembly of triglyceride-rich lipoproteins. Transcription of the apoB gene occurs mainly in the small intestine and liver of adult animals. ApoB mRNAs are translated into single polypeptides of 2152 (apoB48) or 4536 (apoB100) amino acids in the intestine and liver, respectively. Unlike other secretory proteins, which are co-translationally inserted into the endoplasmic reticulum (ER) lumen, apoB is co-translationally integrated, at least transiently, into the ER membranes in a transmembrane orientation (Dixon, J. L. and H. N. Ginsberg 1993 *J. Lipid Res.* 34:167-179; Vance, J. E. and D. E. Vance 1990 *Ann. Rev. Nutr.* 10:337-356; Gibbons, G. F. 1990 *Biochem. J.* 268:1-13; Yao, Z. and R. S. McLeod 1994 *Biochim. Biophys. Acta* 1212:152-166; Sparks, J. D. and C. E. Sparks 1994 *Biochim. Biophys. Acta* 1215:9-32; Hussain, M. M. et al. 1996 *Biochim. Biophys. Acta* 1300:151-170; Innerarity, T. L. et al. 1996 *J. Biol. Chem.* 271:2353-2356). Translocation of apoB across the ER membrane is inefficient and probably determines lipoprotein production (Sakata, N. et al. 1993 *J. Biol. Chem.* 268:22967-22970; Bonnardel, J. A. and R. A. Davis 1995 *J. Biol. Chem.* 270:28892-28896). It is believed that apoB is lipidated even before completion of peptide synthesis as incompletely synthesized apoB polypeptides are secreted as lipoprotein particles by cells incubated with puromycin, a treatment which stops protein synthesis by releasing peptides from ribosomes (Boren, J. et al. 1992 *J. Biol. Chem.* 267: 9858-9867; Spring, D. J. et al. 1992 *J. Biol. Chem.* 267:14389-14845). Lipidation of apoB results in the release of apoB from the ER membrane and in the formation of primordial lipoproteins.

[0004] Microsomal triglyceride transfer protein (MTP) also plays an important role in lipoprotein assembly. The early lipidation of nascent apoB polypeptides requires MTP. Purified MTP activity consists of two subunits of 55 and 97 kDa. The 97 kDa subunit is essential for lipid transfer activity and is defective in abetalipoproteinemia patients who lack apoB-containing lipoproteins in their plasma (Sharp, D. et al. 1993 *Nature* 365:65-69; Wetterau, J. R. et al. 1992 *Science* 258:999-1001; Gregg, R. E. and J. R. Wetterau 1994 *Curr. Opin. Lipidol.* 5:81-86). The 55 kDa protein disulfide isomerase (PDI) subunit is required to keep the larger subunit in solution and to retain it in the ER (Wetterau, J. R. et al. 1991 *Biochem.* 30:9728-9735; Ricci, B. 1995 *J. Biol. Chem.* 270:14281-14285).

[0005] A direct correlation between MTP activity and lipoprotein assembly has been demonstrated in vitro by co-expressing apoB and MTP in cells that do not secrete

lipoproteins (Gordon, D. A. et al. 1994 *Proc. Natl. Acad. Sci.* 91:7628-7632; Leiper, J. M. et al. 1994 *J. Biol. Chem.* 269:21951-21954; Gretch, D. G. et al. 1996 *J. Biol. Chem.* 271:8682-8691). In these studies, expression of apoB cDNAs resulted in the intracellular synthesis and degradation of apoB polypeptides, but no lipoprotein secretion. In contrast, co-transfection of these apoB-expressing cells with MTP resulted in the synthesis and secretion of apoB polypeptides (Gordon, D. A. et al. 1994 *Proc. Natl. Acad. Sci.* 91:7628-7632; Leiper, J. M. et al. 1994 *J. Biol. Chem.* 269:21951-21954; Gretch, D. G. et al. 1996 *J. Biol. Chem.* 271:8682-8691).

[0006] U.S. Pat. No. 5,595,872 and WO 96/40640 describe novel compounds identified as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein secretion which are believed to be useful in treating pancreatitis, obesity, hypercholesterolemia, hypertriglyceridemia, hyperlipidemia, diabetes and atherosclerosis. The ability of these compounds to inhibit microsomal triglyceride transfer protein and/or apolipoprotein secretion was determined by measuring triglyceride secretion from human hepatoma cells in the presence and absence of compounds. Haghpassand et al., 1996 *J. Lipid Research* 37:1468-1480.

[0007] It has been suggested that MTP assists in the translocation of nascent apoB from the ER membrane (Gretch, D. G. et al. 1996 *J. Biol. Chem.* 271:8682-8691). Recently, evidence has been presented for a transient interaction between apoB and MTP in HepG2 cells using co-immunoprecipitations (Wu, X. J. et al. 1996 *J. Biol. Chem.* 271:10277-10281; Patel, S. B. and S. M. Grundy 1996 *J. Biol. Chem.* 271:18686-18694).

[0008] Assays for studying the interactions between MTP and apo-B-containing lipoproteins have been described by Bakillah et al. (Ninth Annual Mid-Atlantic Lipid Research Symposium, March 12-14, 1997). Using these assays, MTP was shown to interact with the N-terminus of apoB by ionic interactions which are modulated by phospholipids.

[0009] Little is known, however, concerning the biochemical, biophysical, or molecular nature of MTP/apoB interactions. Furthermore, those factors that play a role in the dissociation of MTP from nascent lipoproteins prior to secretion are not known.

[0010] MTP has been shown to exist in three different forms in the lumen of the endoplasmic reticulum; free, associated with lipids and bound to apo B. The specific binding site for MTP has now been identified and characterized. Further, the lipid associated MTP has been shown to bind to apoB with higher affinity. In addition, assays have been developed to study the association of MTP with lipid complexes. Accordingly, the present invention relates to methods of identifying compounds which inhibit the interaction of MTP or MTP/lipid complexes with apoB and the binding of MTP to lipid complexes. Compounds identified by these methods are useful in altering the secretion of lipids and lipoproteins.

**SUMMARY OF THE INVENTION**

[0011] An object of the present invention is to provide a method of identifying compounds which modulate lipid secretion which comprises screening compounds in an assay which measures binding of MTP to a MTP specific binding



site on apolipoprotein B. Compounds identified in the assay as inhibitors or inducers of binding of MTP to the MTP specific binding site on apoB should decrease or increase, respectively, lipid secretion.

**[0012]** Another object of the present invention is to provide a method of identifying compounds which modulate lipid secretion which comprises screening compounds in an assay which measures binding of MTP-lipid complexes to apoB. Compounds identified in the assay as inhibitors or inducers of binding of MTP-lipid complexes to apoB should decrease or increase, respectively, lipid secretion.

**[0013]** Yet another object of the present invention is to provide a method of identifying compounds that inhibit or increase the association of MTP with lipid complexes. These compounds may also modulate lipid secretion.

#### DETAILED DESCRIPTION OF THE INVENTION

**[0014]** Atherosclerosis is associated with a variety of disorders including diabetes mellitus, hypertension, familial hypercholesterolemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia, familial hypoalphalipoproteinemia, hypothyroidism, cholesterol ester storage disease, systemic lupus erythematosus, and homocysteinemia. Much research into this disease has been focused on identifying risk factors common to those people affected by atherosclerosis. High plasma lipid and lipoprotein levels have been identified as risk factors for atherosclerosis. Accordingly, lowering plasma lipid levels has become a national goal and new approaches to decreasing lipid levels are required.

**[0015]** A microsomal triglyceride transfer protein (MTP) specific binding site on apoB has now been identified and characterized. In addition, methods have now been developed to study the association of MTP with lipid complexes. MTP binding to apoB is important as an early step in the lipidation of lipoproteins, which leads to increased secretion of these lipoproteins into the blood. Identifying agents that inhibit the binding of apoB and MTP will lead to decreasing apoB secretion. The separate step in synthesis of larger lipoproteins is believed to involve binding of MTP/lipid complexes to apoB. Therefore, inhibition of the binding of MTP/lipid complexes to apoB is another way to decrease levels of lipoproteins in blood. Thus, knowledge of the MTP specific binding site is useful in the development of assays to identify compounds which specifically modulate binding of MTP or MTP/lipid complexes to apoB. Compositions which modulate binding, i.e., increase or decrease binding of MTP or MTP/lipid complexes to the identified MTP specific binding site of apoB are useful in modulating lipoprotein biosynthesis and secretion.

**[0016]** Identification of MTP specific binding site of apoB

**[0017]** Different regions of apoB were expressed as FLAG/apoB chimeras. FLAG (DYKDDDDK) SEQ ID No. 1 is an octapeptide that is commonly used as an epitope tag. cDNAs were transiently transfected into COS cells and conditioned media were used to examine the secretion of FLAG/apoB chimeras using an anti-FLAG monoclonal antibody, M2 (Table 1). Microtiter wells were coated with M2 (3  $\mu$ g/well) or purified, heterodimeric MTP (1  $\mu$ g/well). Wells were incubated in triplicate with 100  $\mu$ l of different

conditioned media, washed, and then bound peptides were quantified using polyclonal sheep anti-human apoB antibodies and alkaline phosphate-labeled anti-sheep IgG (Hussain, M. M. et al. 1997. *Biochemistry* 36:13060-13067). The optical densities were determined at 405 nm.

TABLE 1

Binding of Different apoB Sequences to Immobilized MTP				
apoB Sequences (amino acids)	Anti-FLAG M2 (O.D.) <sup>1</sup>	MTP (O.D.)	Ratio (MTP/M2)	Binding (% of 250-570)
270-570	0.76 (0.10) <sup>2</sup>	0.71 (0.15)	0.93	100
1-300	0.85 (0.02)	0.03 (0.02)	0.04	4
1-502	0.73 (0.11)	0.18 (0.07)	0.25	27
No DNA	0.00	0.00	—	—

<sup>1</sup>O.D. = optical density reading

<sup>2</sup>Values in parentheses represents the standard deviation.

**[0018]** Thus, FLAG/apoB chimeras containing amino acids 1-300, 270-570, and 1-502 were secreted to a similar extent, which is consistent with earlier metabolic labeling studies (Shelness, G. S. et al. 1994. *J. Biol. Chem.* 269:9310-9318).

**[0019]** The binding of secreted peptides to immobilized MTP was also studied and compared with their binding to M2 (Table 1). Similar amounts of amino acids 270-570 bound to M2 and MTP (MTP:M2 ratio of 0.93). In contrast, amino acids 1-502 interacted poorly with immobilized MTP with the amount bound to MTP being only 25% of that bound to M2. Thus, when compared to amino acids 270-570, amino acids 1-502 exhibited only 30% of the MTP binding activity. Accordingly, optimum MTP binding occurred with amino acids 270-570 of apoB and truncation of amino acids 502 to 570 resulted in significant (>70%) loss of binding.

**[0020]** Binding interactions were also studied in solution. In these experiments, MTP or M2 was incubated with radiolabeled amino acids 1-300 and 270-570 and complexes were recovered by immunoprecipitation with antibodies to MTP or M2. The amount of amino acids 1-300 co-immunoprecipitated with M2 was six-fold higher than that of amino acids 270-570 indicating that the amount of amino acids 1-300 secreted was much higher. Nonetheless, only amino acids 270-570 was co-immunoprecipitated with MTP. The amount of amino acids 270-570 co-immunoprecipitated with M2 and MTP were similar. In control experiments, anti-mouse IgG or anti-MTP IgG did not co-immunoprecipitate amino acids 1-300 or 270-570. Thus, amino acids 270-570 recognizes both soluble and immobilized MTP.

**[0021]** The specific size of the MTP binding site in amino acids 270-570 was examined. Amino acids were deleted from the C-terminus of amino acids 270-570 with consideration be given to truncating polypeptides at naturally occurring proline residues to avoid disruption of helical structures. Plasmids expressing various truncated forms of the 270-570 amino acid sequence were transiently transfected in COS cells, and the amounts of synthesized and secreted peptides were determined by radiolabeling, immunoprecipitation, and exposure to Phosphorimager screens. The amounts of all of the FLAG/apoB chimeras in cell lysates were similar indicating that they were synthesized to



a similar extent by the transfected cells. However, the amounts of secreted chimeras were very different. Amino acids 270-570 was most efficiently secreted by these cells, while amino acids 270-394 was secreted with the least efficiency. The secreted chimeras were also measured by enzyme-linked immunoassay (ELISA) using immobilized M2 (Table 2). The secretion efficiency observed for these peptides was amino acids 270-570>270-509 and 270-430>270-341>270-394, which is consistent with results obtained from radiolabeling and immunoprecipitation.

[0022] The binding of these peptides to MTP was also determined (Table 2). Amounts of amino acids 270-570 which bound to M2 and MTP were similar since the ratio between their binding was close to one. This binding is consistent with the data in Table 1. The ratio between the binding of amino acids 270-509 to M2 and MTP was 0.52 indicating that loss of amino acids 510-570 decreased the binding to MTP by  $\approx 60\%$  (Table 2). Truncation of amino acids 270-570 to amino acids 270-430 and amino acids 270-341 resulted in complete loss of binding to MTP. This loss was not due to low levels of the chimeras being secreted because the binding of amino acids 270-430 to M2 was similar to that observed for amino acids 270-509 as determined by the extent of color development. It is believed that removal of amino acids 430-570 resulted in loss of MTP binding. Thus, these studies indicate that an MTP binding site is present within amino acids 430-570 apoB or these amino acids are crucial for MTP binding.

TABLE 2

Effect of C-Terminal Truncations on Binding to Immobilized MTP				
apoB Sequences (amino acids)	Anti-FLAG M2 (O.D.) <sup>1</sup>	MTP (O.D.)	Ratio (MTP/M2)	Binding (% of 270-570)
270-570	0.59 (0.02) <sup>2</sup>	0.53 (0.05)	0.90	100
270-509	0.42 (0.03)	0.22 (0.02)	0.52	58
270-430	0.40 (0.02)	0.03 (0.02)	0.08	9
270-394	0.05 (0.02)	0.00 (0.01)	0.00	0.00
270-341	0.27 (0.03)	0.00 (0.01)	0.00	0.00

<sup>1</sup>O.D. = optical density reading

<sup>2</sup>Values in parentheses represents the standard deviation.

[0023] The region of apoB containing amino acids 430-570 was subjected to secondary structure prediction by the Chou-Fasman method using the Wisconsin Sequence Analysis Package of the Genetics Computer Group. This method predicted two  $\alpha$ -helices consisting of amino acids 496-508 and 529-541. Helical wheel plots of these peptides indicated that helix<sub>496-508</sub> is amphiphilic, while helix<sub>529-541</sub> is not. Both helices contain three positively charged residues. In helix<sub>496-508</sub>, the hydrophilic region contains lys-498, arg-505, and lys-506, whereas helix<sub>529-541</sub> contained lys-530, arg-531 and arg-540. Lysine and arginine residues are crucial for the binding of MTP to apoB. Thus, it is believed that these two  $\alpha$ -helices play an important role in MTP binding to apoB. No other homologous sequences similar to either amino acids 430-570 or the identified helices were identified in the apoB100 molecule.

[0024] Importance of MTP binding at this site in apoB

[0025] Studies were performed to determine whether apoB/MTP binding was required for secretion of apoB-

containing lipoproteins. Several compounds were screened. In the absence of any test compound, 15.47 fmol of low density lipoproteins (LDL) which contain ApoB was bound to immobilized MTP. Two test compounds, AGI-3 and AGI-S17, inhibited 70 to 90% of the binding at 40-50  $\mu$ M concentrations. In contrast, BMS-200150, an inhibitor of MTP's lipid transfer activity, did not effect LDL/MTP binding. The effect of these same compounds on MTP's lipid transfer activity was also evaluated. BMS-200150 inhibited triglyceride transfer activity by 60% at concentrations in the range of 20 to 50  $\mu$ M. AGI-3 inhibited only 20-30% of the activity at these same concentrations. In contrast, AGI-S17 did not inhibit the triglyceride transfer activity of MTP. These data indicate that AGI-3 inhibits both LDL/MTP interactions and MTP activity, whereas AGI-S17 inhibits LDL/MTP binding without affecting lipid transfer activity of MTP.

[0026] The effect of AGI-S17 on the binding of apoB100 to MTP and its monoclonal antibody 1D1, which recognizes amino acids 474-539 in apoB, was examined. AGI-S17 inhibited the binding of apoB100 to MTP by about 60% (4-50  $\mu$ M concentrations) but had no effect on the binding of LDL to 1D1. These data indicate that AGI-S17 specifically inhibits the binding of apoB100 to MTP. The effects of AGI-S17 on apoB18 binding to MTP was also tested. Again, the compound was shown to inhibit binding significantly.

[0027] The effect of AGI-S17 on apoB secretion in cultured cells was examined. HepG2 cells were incubated with different concentrations of AGI-S17 and the secretion of apoB was determined. At 20-30  $\mu$ M concentrations, AGI-S17 had no effect on the amount of apoB secreted. However, treatment of cells with 40  $\mu$ M AGI-S17 resulted in a 48% decrease in the secretion of apoB100.

[0028] The effect of AGI-S17 on the binding of amino acids 270-570 to MTP was also examined. AGI-S17 at a 10  $\mu$ M concentration inhibited 70% of the binding of amino acids 270-570 to immobilized MTP, but did not inhibit binding to immobilized M2.

[0029] The effect of lipids on the binding of MTP with apoB was also examined. Phosphatidylcholine (PC) and sphingomyelin increased the interactions by 2 and 1.5 times respectively. In similar studies, PC vesicles at a concentration of 2.4 mM increased the binding of LDL to MTP by 2 to 4 times. As a control, the effect of phospholipids on the binding of LDL to the monoclonal antibody 1D1 and polyclonal antibodies was studied. 1D1 binds to a portion of the MTP specific binding site on apoB. This antibody also recognizes all subclasses of VLDL and LDL, as well as delipidated apoB. PC slightly increased the binding of LDL to 1D1, whereas sphingomyelin had an inhibitory effect (50% inhibition at 2.4 mM). The effect of PC vesicles on the interaction of apoB to polyclonal antibodies was studied by incubating immobilized LDL with the antibodies both in the presence and absence of PC. PC vesicles had no effect on binding.

[0030] To study the effect of triglycerides (TG) on apoB/MTP specific binding, PC vesicles or emulsions containing two different concentrations of TG were prepared and their effect on LDL binding to MTP was compared with those of PC vesicles with no TG. PC vesicles enhanced LDL binding in a dose-dependent manner. Inclusion of TG had no additional effect on PC-mediated enhanced binding of LDL to MTP.



**[0031]** The effect of different lipids was studied in more detail using PC-based vesicles (Table 3). Again, PC vesicles increased the binding of LDL to MTP by 3-fold. Addition of sphingomyelin (SPH) or cholesterol to PC vesicles had no additional effect. However, inclusion of negatively charged phospholipids, phosphatidyl inositol (PI) and phosphatidyl serine (PS) in PC vesicles significantly decreased the PC-stimulated binding of LDL to MTP. These results indicate that zwitterionic phospholipids promote, whereas negatively charged phospholipids decrease apoB-MTP interactions.

TABLE 3

Effect of Different Lipids on Interactions Between apoB and MTP					
Vesicles (mM)	n <sup>2</sup>	Net Vesicle Charge	LDL Bound (fmol)	Percent Inhibition	p-value <sup>3</sup>
None	6		16.05 <sup>4</sup> (0.98)		
PC (2.4)	3	0.00	46.79 (2.83)		
PC (4.8)	3	0.00	45.20 (1.02)		
PC + sphingomyelin (2.4 + 2.4)	3	0.00	47.32 (0.95)	0.00	
PC + Chol (2.4 + 2.4)	3	0.00	42.03 (0.37)	7	
PC + PI (2.4 + 2.4)	3	-1	26.72 (0.74)	41	<0.001
PC + PS (2.4 + 2.4)	3	-1	33.28 (1.01)	26	<0.001

<sup>1</sup>Type of vesicle tested, concentration in parentheses.

<sup>2</sup>n = number of wells used per treatment

<sup>3</sup>Significant differences evaluated using a Student's t-test

<sup>4</sup>Mean values reported with standard deviation in parentheses

**[0032]** The effect of phospholipids on the kinetic parameters of apoB-MTP binding was examined. It was found that the effect of phospholipid vesicles on the binding of LDL to immobilized MTP was more pronounced at lower concentrations. No significant binding of LDL to MTP could be observed at low concentrations ( $\leq 3$  nM) in the absence of vesicles. However, the effect of vesicles was significant at  $\leq 12.5$  nM of LDL. At higher concentrations the binding of LDL to immobilized MTP in the presence and absence of vesicles was not significantly different. Nonlinear regression analysis revealed that phospholipids decreased the dissociation constant ( $K_d$ ;  $23 \pm 8$  versus  $69 \pm 6$ , mean  $\pm$  standard error) by three-fold without significantly affecting the maximum binding capacity ( $B_{max}$ ;  $13 \pm 0.5$  versus  $10 \pm 1.2$ , mean  $\pm$  standard error). In four other experiments, decreases in  $K_d$  ranged between 1.5- to 3-fold. The effect of phospholipid vesicles on the binding of <sup>125</sup>I-MTP to immobilized LDL was also examined. In these experiments, the binding of <sup>125</sup>I-MTP in the absence of phospholipids did not reach saturation, and thus,  $K_d$  and  $B_{max}$  values were not determined. Nonetheless, the increase in the binding of <sup>125</sup>I-MTP was significantly higher (3-fold at 2-8 nM) at lower concentrations than at higher concentrations (2-fold at 17 and 34 nM). Furthermore, at the highest concentration tested (68 nM) the differences in binding were no longer statistically significant, indicating that the effect of PC vesicles was probably on the  $K_d$  and not on the  $B_{max}$ . Considered together, these results indicated that phospholipid vesicles increase affinity between apoB and MTP without altering the number of binding sites.

**[0033]** The interactions between apoB28 with PC vesicles were also examined. Conditioned medium obtained from McA-RH7777 cells stably transfected with human apoB28 was incubated with lipid vesicles. Preincubation of conditioned medium with PC vesicles resulted in a slight shift of apoB28 peak toward lower density. ApoB28 was separated from the lipid vesicles. Fractions containing apoB28 were pooled, dialyzed and their binding to immobilized MTP examined. The binding of apoB28 preincubated with or without phospholipid vesicles was similar, indicating that interactions between lipids and apoB28 were probably not important for the enhanced interactions between apoB and MTP.

**[0034]** Further experiments were performed to examine MTP interactions with PC vesicles. Studies were done to determine whether MTP binds to PC vesicles by incubating MTP with labeled vesicles and then determining the floatation properties of the vesicles. PC vesicles had a floatation density of plasma LDL and eluted as a single homogeneous peak. In contrast, incubation of vesicles with MTP resulted in a decrease in the vesicle peak and in the appearance of a hump at the trailing end of the vesicle peak. These data indicate that MTP changed the floatation properties of some of the PC vesicles, most likely by interaction with the vesicles. To determine whether MTP interacted with PC vesicles, <sup>125</sup>I-MTP was incubated with or without PC vesicles and subjected to density gradient ultracentrifugation. MTP, incubated without lipid vesicles, was recovered in the bottom fractions corresponding to a density  $>1.21$  g/ml. This was designated peak A (fractions 21-24). In contrast, MTP incubated with vesicles was distributed in two fractions. One fraction was recovered as lipid-poor MTP (designated peak B, fractions 21-24), similar to that observed for MTP alone (peak A). This fraction may represent MTP with 1-2 mol of lipid molecules. MTP associated with lipids ( $\approx 50\%$ ) was also recovered (designated peak C, fractions 3-9). The profile of MTP associated with vesicles was similar to that observed for vesicles incubated with unlabeled MTP, indicating that MTP interacted with all of the vesicles. Further, vesicles contained various amounts of MTP, leading to two different populations of vesicles containing different amounts of MTP. Thus, these data indicate that MTP forms stable complexes with lipid vesicles.

**[0035]** Binding of MTP/lipid complexes to apoB

**[0036]** To study the binding of lipid associated MTP with LDL, peaks A, B, and C were pooled, dialyzed and then used to study binding to immobilized LDL. The binding of lipid-poor MTP (peak B), which might have acquired few lipid molecules during its incubation with lipid vesicles, to LDL was increased (70%,  $P < 0.005$ ) compared to the binding of MTP not incubated with lipids (peak A). More importantly, the amount of MTP/lipid complexes (peak C) bound to LDL was three-fold higher than when MTP was used alone. These studies indicate that lipid-associated MTP binds better to LDL as compared to lipid-poor and lipid-free MTP. It is believed that MTP forms stable complexes with phospholipid vesicles and these MTP/lipid complexes have higher affinity for apoB.

**[0037]** The binding of apoA-I and apoA-I/lipid complexes to immobilized LDL was examined. ApoA-I incubated with or without lipid vesicles was subjected to ultracentrifugation and apoA-I/lipid complexes were isolated. Binding of

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.